In addition, our analyses identified 16 important metabolic pathways strongly associated with SGLT2 inhibition and the four lung diseases studied (interstitial lung disease, pneumoconiosis, tuberculosis, and asthma), and comprehensively assessed the possible side effects of SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and pneumoconiosis.